Zobrazeno 1 - 10
of 97
pro vyhledávání: '"Thomas Lander"'
Autor:
Price, Curtis
Publikováno v:
Early Music, 1990 Aug 01. 18(3), 493-496.
Externí odkaz:
https://www.jstor.org/stable/3127765
Autor:
Muñoz Flores, Ángel
Publikováno v:
Tiempo y Espacio, Volume: 22, Issue: 57, Pages: 32-45, Published: JUN 2012
El proyecto Gran Colombiano, había comenzado a naufragar a partir de 1826, se hacía insostenible, sobre todo después de la Batalla de Ayacucho de 1824. En 1830, al emerger Venezuela como república independiente, había todo por hacer, un territor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______621::29fa61daf490ee247aa57b1f091b4bb9
http://www.scielo.org.ve/scielo.php?script=sci_arttext&pid=S1315-94962012000100002&lng=en&tlng=en
http://www.scielo.org.ve/scielo.php?script=sci_arttext&pid=S1315-94962012000100002&lng=en&tlng=en
Autor:
Ingmar Hoerr, Alexander Knuth, Alfred Zippelius, Tanja Strack, Jochen Probst, Ulrike Gnad-Vogt, Florian Von Der Muelbe, Djordje Atanackovic, Andreas Gröschel, Frank Mayer, Michael Thomas, Volker Wiegand, Henoch S. Hong, Anke Muth, Andreas Schröder, Lotta von Boehmer, Folker Schneller, Karl-Josef Kallen, Martin Sebastian, Thomas Lander, Jan Stöhlmacher, Birgit Scheel, Martin Reck, Sven D. Koch, Mariola Fotin-Mleczek, Helga Bernhard
Publikováno v:
Cancer immunology, immunotherapy : CII. 68(5)
CV9201 is an RNActive®-based cancer immunotherapy encoding five non-small cell lung cancer-antigens: New York esophageal squamous cell carcinoma-1, melanoma antigen family C1/C2, survivin, and trophoblast glycoprotein. In a phase I/IIa dose-escalati
Autor:
Christian Hampel, Kurt Miller, Giorgio Parmiani, Florian Von Der MüLBE, Gerd Rippin, Mariola Fotin-Mleczek, Tobias Maurer, Dieter Jocham, Lutz Trojan, Arnulf Stenzl, Thomas Lander, Hubert Kübler, Frank vom Dorp, Jochen Probst, Ulrike Gnad-Vogt, Ingmar Hoerr, Steffen Wedel, Wolfgang Schultze-Seemann, Karl-Josef Kallen, Birgit Scheel
Publikováno v:
Journal for Immunotherapy of Cancer
Background CV9103 is a prostate-cancer vaccine containing self-adjuvanted mRNA (RNActive®) encoding the antigens PSA, PSCA, PSMA, and STEAP1. This phase I/IIa study evaluated safety and immunogenicity of CV9103 in patients with advanced castration-r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63de357bf676fdec0e5f85b051ff49ab
https://www.ncbi.nlm.nih.gov/pubmed/26082837
https://www.ncbi.nlm.nih.gov/pubmed/26082837
Autor:
Dieter Jocham, L. Pilla, A. Stenzl, Susan Feyerabend, K. Kurt, Christian Hampel, W. Schultze-Seemann, Ulrike Gnad-Vogt, B. Birgit, Thomas Lander, Martin Schostak, S. Wedel, K. Hiller, Hubert Kübler, G. Parmiani, Karl-Josef Kallen, Lutz Trojan, M. Sommerauer, F. Vom Dorp, M. Reindl, Ursula Steiner, Tobias Maurer
Publikováno v:
European Urology Supplements. 11:189
Autor:
Volker Wiegand, Gerd Rippin, Sven D. Koch, Karl-Josef Kallen, Eray Goekkurt, Djordje Atanackovic, Alexander Knuth, Thomas Lander, Frank Mayer, Ulrike Gnad-Vogt, Andreas Groeschel, Martin Sebastian, Jan Stoehlmacher-Williams, Alfred Zippelius, Birgit Scheel, Michael Thomas, Martin Reck, Lotta von Boehmer, Folker Schneller, Helga Bernhard
Publikováno v:
Journal of Clinical Oncology. 30:2573-2573
2573^ Background: Vaccination with mRNA is a novel technology in cancer immunotherapy. CV9201 consists of self-adjuvanted mRNA molecules (RNActive) coding for five non small cell lung cancer (NSCLC)-associated tumor antigens (MAGE-C1, MAGE-C2, NY-ESO
Autor:
K. Hiller, Birgit Scheel, Tobias Maurer, A. Stenzl, Christian Hampel, W. Schultze-Seemann, S. Wedel, Lutz Trojan, Karl-Josef Kallen, F. vom Dorp, Thomas Lander, Hubert Kübler, Susan Feyerabend, Dieter Jocham, Ursula Steiner, M. Sommerauer, Martin Schostak, Kurt Miller, L. Pilla, G. Viatali
Publikováno v:
Journal of Clinical Oncology. 29:4535-4535
4535 Background: CV9103 is a prostate cancer (PCA) vaccine that contains the four antigens PSA (prostate specific antigen), PSCA, PSMA and STEAP1 as self-adjuvanted full-length mRNAs. Methods: Patients with castrate resistant PCA with rising PSA and
Autor:
A. Groeschel, Djordje Atanackovic, Sven D. Koch, R. Bals, Jan Stoehlmacher, S. Schmidt, Alfred Zippelius, Birgit Scheel, Helga Bernhard, Alexander Knuth, Michael Thomas, Thomas Lander, Martin Sebastian, L. von Boehmer, Eray Goekkurt, Frank Mayer, Karl-Josef Kallen, Folker Schneller, Martin Reck
Publikováno v:
Journal of Clinical Oncology. 29:2584-2584
2584 Background: CV9201 is a therapeutic cancer vaccine for non small cell lung cancer (NSCLC) based on a novel vaccination technology using self-adjuvanted mRNA molecules. It comprises five mRNAs encoding NSCLC associated tumor antigens (NY-ESO1, Ma
Publikováno v:
Diabetes. 38:1557-1566
Flow cytometry was recently introduced for the detection of antibodies in human serum to a cultured insulin-secreting rat insulinoma cell line (RINm5F) to investigate humoral immune reactivity in newly diagnosed type I (insulin-dependent) diabetic pa